Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37

Juan Manuel Carreño¹, Hala Alshammary¹, Gagandeep Singh¹, Ariel Raskin¹, Fatima Amanat^{1,2}, Angela Amoako¹, Ana Silvia Gonzalez-Reiche^{2,6}, Adriana van de Guchte⁶, PARIS study group¹, Komal Srivastava¹, Emilia Mia Sordillo³, D. Noah Sather^{4,5}, Harm van Bakel^{6,7,*}, Florian Krammer^{1,3,*} and Viviana Simon^{1,3, 8,9*}

¹Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

²Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

³Department of Pathology, Molecular and Cell Based Medicine Icahn School of Medicine at Mount Sinai, New York, NY, USA

⁴Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States

⁵Department of Pediatrics, University of Washington, Seattle, WA, United States

⁶Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA;

⁷Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

⁸Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

⁹The Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

*To whom correspondence should be addressed: harm.vanbakel@mssm.edu, florian.krammer@mssm.edu, viviana.simon@mssm.edu

PARIS study group (in alphabetical order, Study group/Consortium): Mahmoud Awawda, Radhika Banu, Katherine Beach, Carolina Bermúdez-González, Dominika Bielak, Liyong Cao, Rachel Chernet, Parnavi Desai, Shelcie Fabre, Emily. D. Ferreri, Daniel Floda, Charles Gleason, Hisaaki Kawabata, Zenab Khan, Dr. Giulio Kleiner, Dr. Denise Jarczyszak, Julia Matthews, Wanni Mendez, Dr. Lubbertus CF Mulder, Kayla Dr. Alberto E Paniz-Mondolfi, Russo, Ashley Salimbangon, Dr. Miti Saksena, A. Shin, Levy Sominsky, Johnston Tcheou

Abstract

Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed.¹ However, the emergence of viral variants that are more infectious than the earlier SARS-CoV-2 strains is concerning.² Several of these viral variants have the potential to partially escape neutralizing antibody responses warranting continued immune-monitoring. Here, we tested a number of currently circulating viral variants of concern/interest, including B.1.526 (Iota), B.1.1.7+E484K (Alpha), B.1.351 (Beta), B.1.617.2 (Delta) and C.37 (Lambda) in neutralization assays using a panel of post-mRNA vaccination sera. The assays were performed with authentic SARS-CoV-2 clinical isolates in an assay that mimics physiological conditions. We found only small decreases in neutralization against B.1.526 and an intermediate phenotype for B.617.2. The reduction was stronger against a sub-variant of C.37, followed by B.1.351 and B.1.1.7+E484K. C.37 is currently circulating in parts of Latin America³ and was detected in Germany, the US and Israel. Of note, reduction in a binding assay that also included P.1, B.1.617.1 (Kappa) and A.23.1 was negligible. Taken together, these findings suggest that mRNA SARS-CoV-2 vaccines may remain effective against these viral variants of concern/interest and that spike binding antibody tests likely retain specificity in the face of evolving SARS-CoV-2 diversity.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 in China and has since then caused the coronavirus disease 2019 (COVID-19) pandemic. Vaccines were developed and distributed in record speed with emergency use authorizations as early as December 2020 (in the US). Coronaviruses are an exception among RNA viruses because their replication machinery possesses proofreading activity.⁴ It was, therefore, expected that they would evolve slower than other RNA viruses. The emergence of variant viruses, first in Europe in the summer of 2020⁵⁻⁷ - including in minks in Denmark - and then in late 2020 in the UK⁸, South Africa⁹ and Brazil¹⁰ was a surprising event. Since the detection of these first variants, several other variants of interest (Vols) and variants of concern (VoCs) have spread locally as well as globally. These include B.1.526 (Iota) which emerged in New York City and comprises three different sub-lineages^{11,12}, B.1.427/B.1.429 (Epsilon) which emerged in California,¹³ C.37 (Lambda) which emerged in Peru,³ B.1.617.2 (Delta) and B.1.617.1 (Kappa) which emerged in India,¹⁴ B.1.1.7+E484K (Alpha) which was detected in several countries, as well as A.23.1 which was first detected in Uganda.¹⁵ Several of these lineages are in decline, including B.1.526 and B.1.427/B.1.429 while others such as B.1.617.2 are increasing in prevalence. Many of these variants display extensive changes in the N-terminal domain (NTD) and/or the receptor binding domain (RBD) of spike, both of which harbor neutralizing epitopes. In addition, several of these variants also contain additional mutations in their spike gene that may enhance affinity to human angiotensin converting enzyme 2 (ACE2).¹⁶ These changes may impact negatively on binding and neutralization by vaccine-induced antibodies, which are discussed as mechanistic correlates of protection.^{17,18} It is, therefore, important to monitor neutralizing and binding activity of sera from vaccinees against these variants.

Here, we tested the neutralizing activity of a panel of 30 post mRNA SARS-CoV-2 vaccination sera against the three B.1.526 sublineages, B.1.1.7+E484K, B.1.617.2, B.1.351 and a C.37 sub-variant using a microneutralization assay. This assay was designed to allow for multicycle replication with sera/antibodies being present in the overlay at all times to better mimic physiological conditions.¹⁹ In addition, we performed binding assays against recombinant RBD and full-length spike proteins of several Vols and VoCs.

Results

First, we assessed the neutralizing activity of 30 post-vaccination serum samples from individuals vaccinated with mRNA-1273 (Moderna) or BNT162b2 (Pfizer/BioNTech). This panel of sera is used by the NIAID SARS-CoV-2 Assessment of Viral Evolution (SAVE) 'in vitro' group, which is part of the US Department of Health and Human Services (HHS) SARS-CoV-2 Interagency Group (SIG), to determine the immune escape of different VoCs and Vols.²⁰ The viruses tested in this study include the wild type WA1 isolate as well as clinical isolates derived from nasopharyngeal swabs obtained from patients diagnosed with COVID-19 at the Mount Sinai Health System in New York City, representing B.1.526 (no change in RBD), B.1.526 (E484K), B.1.526 (S477N), B.1.1.7+E484K, B.1.351, B.1.617.2 and a subvariant of C.37 (**Supplementary Table 1, Supplemental Figure 1**). The C.37 subvariant contained additional changes compared to the consensus sequence including a large 13 amino acid deletion instead of G75V and T76I NTD substitutions and an additional E471Q substitution in the RBD. The panel of post-vaccination sera (**Supplementary Table 2**) was tested against these seven viruses in a well-established neutralization assay.¹⁹ In this assay, 60 tissue culture infectious doses of virus per well are pre-incubated with the respective serum dilutions for one hour. The serum/virus mix is then used to infect Vero.E6 cells. After the infection step, the cell culture medium is replaced with fresh medium containing the respective concentration of serum. The assay allows, therefore, for multicycle replication of the test virus in the continuous presence of test serum, which recapitulates infection conditions *in vivo*.

The microneutralization assays showed only modest reductions in neutralizing activity against the three B.1.526 variants compared to the wild type WA1 isolate (**Figure 1**). The geometric mean titer (GMT) of neutralization of the three B.1.526 sublineages was reduced by 1.4-fold (ancestral B.1.526), 1.8-fold (E484K) and 2.3-fold (S477N), respectively. Reduction in neutralizing activity against the B.1.617.2 isolate was moderate with 3-fold change compared to WA1. A more pronounced drop in neutralizing activity was seen with the B.1.1.7+E484K isolate (3.8-fold). As expected and reported before, an even stronger decrease in neutralization (4.2-fold) was found against the B.1.351 isolate. However, the greatest reduction in GMT (4.6-fold) was observed against a C.37 variant isolate. Of note, as explained above, virus isolate PV29369 carries additional substitutions/deletions in spike (see **Supplemental Table 1**) compared to the majority of circulating C.37.

We next determined antibody-binding activity against variant RBDs and spike proteins. The fold-reduction in binding against variant RBDs from B.1.1.7, P.1 and B.1.351 was negligible with a maximum reduction of 1.6-fold against the B.1.351 RBD (**Figure 2A and B**). Similarly, reduction in binding to B.1.1.7, B.1.351, P.1, B.1.617.1 and A.23.1 spike proteins was minimal, again with B.1.351 showing the strongest impact and a 1.4-fold reduction (**Figure 2C and D**).

Discussion

Monitoring the effectiveness of vaccination in the context of evolving viral variants is of great public health concern for control of the COVID-19 pandemic. Indeed, neutralizing antibodies play a major role in protection from COVID-19, as shown both in animal models as well as in humans.^{17,18,21-23} It is, therefore, important to continuously monitor emerging variants and their impact on neutralizing activity of post-vaccination serum. Our data show a spectrum of neutralizing activities against a panel of Vols and VoCs. The least negative impact on neutralization was seen for B.1.526 variant, which is reasonable since this isolate has very few changes in the spike protein (T95I, D253G and D614G) compared to the wild type WA1 isolate. The impact was higher for the B.1.526 isolates that carry, in

addition, E484K or S477N substitutions in the RBD. Interestingly, S477N exerted a stronger impact than E484K, which was surprising given the strong reduction caused by introduction of E484K into the WA1 wild type backbone.²⁴ However, S477N has also been described as escape mutation.²⁵ The reduction in neutralization against B.1.617.2 was moderate, which aligns well with the preserved vaccine effectiveness against this variant.^{26,27} The combination of B.1.1.7 (which already harbors two deletions in the NTD) with E484K led to a substantial reduction in neutralizing activity. However, although B.1.1.7+E484K emerged several times independently, it does not seem to spread well – potentially due to the detrimental effect that the E484K mutation can have on binding affinity to human ACE2.¹⁶ As expected and already shown by several publications,²⁸⁻³³ neutralizing activity to B.1.351 was strongly reduced likely due to the three changes in RBD and extensive changes in the NTD. Interestingly, neutralizing activity was even more reduced for the local isolate of C.37 used in the current study which has more extensive changes in the NTD ($\Delta 63-75$, $\Delta 246-252$) and the RBD (L452Q, E471Q, F490S) compared to the predominant C.37 variant (NTD: G75V, T76I, $\Delta 246-252$; RBD: L452Q, F490S).³ While there was a strong reduction in neutralizing activity of post-vaccination sera against this variant, all 30 sera retained at least partial neutralization activity against this C37 variant virus which may indicate that – similar to B.1.351³⁴ – mRNA vaccines will remain effective against these Vols. Of note, the additional changes in the local C.37 isolate likely contribute to the immune evasion phenotype shown here and should be seen as worst case scenario for the C.37 variant.

Another interesting finding was that the reduction in binding activity to variant RBD and spike proteins was negligible. However, while neutralization activity is mostly dependent on only a few epitopes in the RBD and NTD, many more binding epitopes exist on the spike,¹⁶ which may explain our findings. Interestingly, a recent study found even better correlation between binding activity and vaccine effectiveness than for neutralizing activity and vaccine effectiveness.¹⁷ This may indicate that binding antibodies – even if they lack neutralizing activity – are involved in protection. It is well known that non-neutralizing antibodies raised upon infection or vaccination by ebolavirus or influenza viruses, can be protective via Fc-mediated effector functions.³⁵⁻³⁸ Future studies are needed to establish if this is also the case for SARS-CoV-2. However, the finding that the drop in binding activity is negligible even against spike proteins from variants with extensive changes like B.1.351 is reassuring in that context.

Materials and Methods

Cells and SARS-CoV-2 isolates. Vero.E6 cells were cultured in Dulbecco's Modified Eagles Medium (DMEM, Corning) containing 10% fetal bovine serum (FBS, Corning) supplemented with 100 U/ml penicillin, 100 μ g/ml streptomycin (Gibco). Nasopharyngeal swab specimens were collected as part of the routine SARS-CoV-2 surveillance conducted by the Mount Sinai Pathogen Surveillance program (IRB approved, HS#13-00981). Specimens were selected for viral culture on Vero-E6 cells based on the complete viral genome sequence information.³⁹ Viruses were grown in Vero.E6 cells for 4-6 days; the supernatant was clarified by centrifugation at 4,000 g for 5 minutes and aliquots were frozen at -80°C for long term use. Expanded viral stocks were sequence-verified and titered on Vero.E6 cells prior to use in microneutralization assays.

Phylogeny of SARS-CoV-2 lineages. The phylogenetic relationships of the SARS-CoV-2 isolates from the Pathogen Surveillance Program of the Mount Sinai Health System are depicted in a New York focused

background from GISAID. The timed tree was built with nextstrain.org/sars-cov-2. PANGO lineages are depicted for the Vols and VoCs used in the neutralization assays.

Post vaccination serum samples. A panel of 30 post-vaccination sera was generated for use and distribution by BEI Resources for the NIAID SAVE “*in vitro*” group (**Supplementary Table 2**). Briefly, 30 participants enrolled in the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) study (reviewed and approved by the Mount Sinai Hospital Institutional Review Board; IRB-20-03374) were invited to provide additional serum samples after receiving their second mRNA vaccine dose. All specimens were coded prior to processing, banking and sharing with BEI Resources. 15 participants had received two doses of the mRNA-1273 (Moderna) and 15 participants had received two doses of the BNT162b2 (Pfizer/BioNTech). The majority of participants were naïve prior to vaccination with 4-5 COVID-19 survivors being included each vaccine group.

ELISA. Antibody titers in sera from vaccinees were determined by a research grade enzyme-linked immunosorbent assay (ELISA) using recombinant versions of the receptor binding domain (RBD) and the spike (S) of wild type SARS-CoV-2 and variant viruses (RBD: WT/Wuhan-1, B.1.1.7, B.1.351, P.1; spike: WT/Wuhan-1, B.1.1.7, B.1.351, P.1, B.1.617.1, A.23.1). Briefly, 96-well microtiter plates (Thermo Fisher) were coated with 50 µl/well of recombinant protein (2 µg/ml) overnight at 4 °C. Plates were washed three times with phosphate-buffered saline (PBS; Gibco) supplemented with 0.1% Tween-20 (PBS-T; Fisher Scientific) using an automatic plate washer (BioTek). For blocking, PBS-T containing 3% milk powder (American Bio) was used. After 1-hour incubation at room temperature (RT), blocking solution was removed and initial dilutions of heat-inactivated sera (in PBS-T 1%-milk powder) were added to the plates, followed by 2-fold serial dilutions. After 2-hour incubation, plates were washed three times with PBS-T and 50 µl/well of the pre-diluted secondary antibody anti-human IgG (Fab-specific) horseradish peroxidase antibody (produced in goat; Sigma, A0293) diluted 1:3,000 in PBS-T containing 1% milk powder were added. After 1-hour incubation at RT, plates were washed three times with PBS-T and SigmaFast o-phenylenediamine dihydrochloride (Sigma) was added (100 µl/well) for 10min, followed by addition of 50 µl/well of 3 M hydrochloric acid (Thermo Fisher) to stop the reaction. Optical density was measured at a wavelength of 490 nm using a plate reader (BioTek). Area under the curve (AUC) values were calculated and plotted using GraphPad Prism 7.

Microneutralization assay. Sera from vaccinees were used to assess the neutralization of wild type SARS-CoV-2 and selected Vols and VoCs (**Supplementary Table 1**). All procedures were performed in the Biosafety Level 3 (BSL-3) facility at the Icahn School of Medicine at Mount Sinai following standard safety guidelines. Remdesivir was used as a control for wild type and variant viruses to monitor assay variation. The day before infection, Vero E6 cells were seeded in 96-well high binding cell culture plates (Thermo Fisher) at a density of 20,000 cells/well in complete Dulbecco’s Modified Eagle Medium (cDMEM). After heat inactivation of sera (56°C for 1 hour), serum samples were serially diluted (3-fold) in minimum essential media starting at 1:10. For dilutions of sera, infection media consisting of minimum essential media (MEM, Gibco) supplemented with 2 mM L-glutamine, 0.1% sodium bicarbonate (w/v, Gibco), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Gibco), 100 U/ml penicillin, 100 µg/ml streptomycin (Gibco) and 0.2% bovine serum albumin (MP Biomedicals) was used. Vero E6 cells were seeded in 96-well high binding cell culture plates (Thermo Fisher) at a density of 20,000 cells/well in complete Dulbecco’s Modified Eagle Medium (cDMEM). On the next day, sera dilutions were incubated with 1,000 tissue culture infectious dose 50 (TCID₅₀) of wt USA-WA1/2020 SARS-CoV-2 or the corresponding variant virus for 1 hour at RT, followed by transfer of 120µl of virus-sera mix to

Vero-E6 plates. Infection was led to proceed for 1 hour at 37°C and inoculum was removed. 100 µl/well of the corresponding antibody dilutions plus 100µl/well of infection media supplemented with 2% fetal bovine serum (Gibco) were added to the cells. Plates were incubated for 48h at 37°C.

For staining of the nucleoprotein antigen, cells were fixed by addition of 150 µl/well of a 10% formaldehyde solution and incubated overnight at 4°C. Fixed cell monolayers were washed with PBS (Gibco) and permeabilized with 150 µl/well of PBS, 0.1% Triton X-100 for 15 min at RT. Permeabilization solution was removed, plates were washed with 200 µl/well of PBS twice and 200 µl/well of blocking solution consisting of PBS 3% milk (American Bio) were added for 1 h at RT. Blocking solution was removed and 100 µl/well of mAb 1C7 (anti-SARS nucleoprotein antibody produced in house) diluted in PBS 1% milk (American Bio) at a 1:4000 dilution were added for 1 h at RT. Primary antibody was removed and plates were washed with 200 µl/well of PBS twice, followed by addition of 100 µl/well of goat anti-mouse IgG-HRP (Rockland Immunochemicals) diluted in PBS 1% milk (American Bio) 1:3000. After 1 hour incubation, antibody solution was removed, plates were washed twice with PBS and 100 µl/well of o-phenylenediamine dihydrochloride (Sigmafast OPD; Sigma-Aldrich) were added for 10 min at RT. The reaction was stopped by addition of 50 µl/well of HCl 3M (Thermo Fisher Scientific). Optical density (OD) was measured (490 nm) with a microplate reader (Synergy H1; Biotek). Initial subtraction of background and calculation of the percentage of neutralization with respect to the “virus only” control was done in excel. A non linear regression curve fit analysis, using Prism 9 software (GraphPad), was performed to calculate the inhibitory dilution 50% (ID₅₀), using top and bottom constraints of 100% and 0% respectively.

Acknowledgments

We would like to thank the study participants for their generosity and willingness to participate in longitudinal COVID19 research studies. None of this work would be possible without their contributions. We would like to thank Dr. Randy A. Albrecht for oversight of the conventional BSL3 biocontainment facility, which makes our work with live SARS-CoV-2 possible. We are also grateful for Mount Sinai’s leadership during the COVID-19 pandemic. We want to especially thank Drs. Peter Palese, Carlos Cordon-Cardo, Dennis Charney, David Reich and Kenneth Davis for their support. This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051. This work was also partially funded by the Centers of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C), and by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384); and by anonymous donors. Finally, this effort was also supported by the Serological Sciences Network (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government.

Conflict of Interest Statement

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon and Fatima Amanat are also listed on the serological assay patent application as co-

242 inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2.
243 Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer,
244 Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-
245 CoV-2.
246

References

- 1 Krammer, F. SARS-CoV-2 vaccines in development. *Nature* **586**, 516-527, doi:10.1038/s41586-020-2798-3 (2020).
- 2 Harvey, W. T. *et al.* SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol* **19**, 409-424, doi:10.1038/s41579-021-00573-0 (2021).
- 3 Romero, P. E. *et al.* The Emergence of SARS-CoV-2 Variant Lambda (C.37) in South America. *medRxiv*, 2021.2006.2026.21259487, doi:10.1101/2021.06.26.21259487 (2021).
- 4 Denison, M. R., Graham, R. L., Donaldson, E. F., Eckerle, L. D. & Baric, R. S. Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. *RNA Biol* **8**, 270-279, doi:10.4161/rna.8.2.15013 (2011).
- 5 Korber, B. *et al.* Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell* **182**, 812-827.e819, doi:10.1016/j.cell.2020.06.043 (2020).
- 6 Thomson, E. C. *et al.* Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. *Cell*, doi:10.1016/j.cell.2021.01.037 (2021).
- 7 Larsen, H. D. *et al.* Preliminary report of an outbreak of SARS-CoV-2 in mink and mink farmers associated with community spread, Denmark, June to November 2020. *Euro Surveill* **26**, doi:10.2807/1560-7917.ES.2021.26.5.210009 (2021).
- 8 PHE.
(https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959426/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5.pdf, 2021).
- 9 Tegally, H. *et al.* Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. *medRxiv*, 2020.2012.2021.20248640, doi:10.1101/2020.12.21.20248640 (2020).
- 10 Faria, N. R. *et al.* Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science* **372**, 815-821, doi:10.1126/science.abh2644 (2021).
- 11 Thompson, C. N. *et al.* Rapid Emergence and Epidemiologic Characteristics of the SARS-CoV-2 B.1.526 Variant - New York City, New York, January 1-April 5, 2021. *MMWR Morb Mortal Wkly Rep* **70**, 712-716, doi:10.15585/mmwr.mm7019e1 (2021).
- 12 Annavajhala, M. K. *et al.* A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York. *medRxiv*, doi:10.1101/2021.02.23.21252259 (2021).
- 13 McCallum, M. *et al.* SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. *Science*, doi:10.1126/science.abi7994 (2021).
- 14 Kumar, S. Second wave of COVID-19: Emergency situation in India. *J Travel Med*, doi:10.1093/jtm/taab082 (2021).
- 15 Bugembe, D. L. *et al.* A SARS-CoV-2 lineage A variant (A.23.1) with altered spike has emerged and is dominating the current Uganda epidemic. *medRxiv*, 2021.2002.2008.21251393, doi:10.1101/2021.02.08.21251393 (2021).
- 16 Amanat, F. *et al.* SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. *Cell*, doi:10.1016/j.cell.2021.06.005 (2021).
- 17 Earle, K. A. *et al.* Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine*, doi:10.1016/j.vaccine.2021.05.063 (2021).
- 18 Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*, doi:10.1038/s41591-021-01377-8 (2021).
- 19 Amanat, F. *et al.* An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. *Curr Protoc Microbiol* **58**, e108, doi:10.1002/cpmc.108 (2020).
- 20 Walensky, R. P., Walke, H. T. & Fauci, A. S. SARS-CoV-2 Variants of Concern in the United States- Challenges and Opportunities. *JAMA* **325**, 1037-1038, doi:10.1001/jama.2021.2294 (2021).

294 21 McMahan, K. *et al.* Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature*
295 **590**, 630-634, doi:10.1038/s41586-020-03041-6 (2021).

296 22 Krammer, F. Correlates of protection from SARS-CoV-2 infection. *Lancet* **397**, 1421-1423,
297 doi:10.1016/S0140-6736(21)00782-0 (2021).

298 23 Krammer, F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. *Nature*
299 *Medicine*, doi:10.1038/s41591-021-01432-4 (2021).

300 24 Jangra, S. *et al.* SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. *Lancet*
301 *Microbe*, doi:10.1016/S2666-5247(21)00068-9 (2021).

302 25 Liu, Z. *et al.* Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum
303 antibody neutralization. *Cell Host Microbe* **29**, 477-488.e474, doi:10.1016/j.chom.2021.01.014
304 (2021).

305 26 Sheikh, A., McMenamin, J., Taylor, B., Robertson, C. & Collaborators, P. H. S. a. t. E. I. SARS-CoV-
306 2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
307 *Lancet* **397**, 2461-2462, doi:10.1016/S0140-6736(21)01358-1 (2021).

308 27 Bernal, J. L. *et al.* Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. *medRxiv*,
309 2021.2005.2022.21257658, doi:10.1101/2021.05.22.21257658 (2021).

310 28 Edara, V. V. *et al.* Infection- and vaccine-induced antibody binding and neutralization of the
311 B.1.351 SARS-CoV-2 variant. *Cell Host Microbe* **29**, 516-521.e513,
312 doi:10.1016/j.chom.2021.03.009 (2021).

313 29 Wang, P. *et al.* Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody
314 Neutralization. *bioRxiv*, 2021.2001.2025.428137, doi:10.1101/2021.01.25.428137 (2021).

315 30 Zhou, D. *et al.* Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-
316 induced sera. *Cell* **184**, 2348-2361.e2346, doi:10.1016/j.cell.2021.02.037 (2021).

317 31 Planas, D. *et al.* Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing
318 antibodies. *Nat Med* **27**, 917-924, doi:10.1038/s41591-021-01318-5 (2021).

319 32 Liu, Y. *et al.* Neutralizing Activity of BNT162b2-Elicited Serum. *N Engl J Med* **384**, 1466-1468,
320 doi:10.1056/NEJMc2102017 (2021).

321 33 Wu, K. *et al.* Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. *N Engl J Med* **384**,
322 1468-1470, doi:10.1056/NEJMc2102179 (2021).

323 34 Abu-Raddad, L. J., Chemaitelly, H., Butt, A. A. & Vaccination, N. S. G. f. C.-. Effectiveness of the
324 BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med*,
325 doi:10.1056/NEJMc2104974 (2021).

326 35 Saphire, E. O., Schendel, S. L., Gunn, B. M., Milligan, J. C. & Alter, G. Antibody-mediated
327 protection against Ebola virus. *Nat Immunol* **19**, 1169-1178, doi:10.1038/s41590-018-0233-9
328 (2018).

329 36 Saphire, E. O. *et al.* Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines
330 Features that Contribute to Protection. *Cell* **174**, 938-952.e913, doi:10.1016/j.cell.2018.07.033
331 (2018).

332 37 Henry Dunand, C. J. *et al.* Both Neutralizing and Non-Neutralizing Human H7N9 Influenza
333 Vaccine-Induced Monoclonal Antibodies Confer Protection. *Cell Host Microbe* **19**, 800-813,
334 doi:10.1016/j.chom.2016.05.014 (2016).

335 38 Asthagiri Arunkumar, G. *et al.* Broadly Cross-Reactive, Nonneutralizing Antibodies against
336 Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against
337 Lethal Viral Challenge in Mice. *J Virol* **93**, doi:10.1128/JVI.01696-18 (2019).

338 39 Gonzalez-Reiche, A. S. *et al.* Introductions and early spread of SARS-CoV-2 in the New York City
339 area. *Science*, doi:10.1126/science.abc1917 (2020).

340

Figure Legends

Figure 1. Neutralizing activity of post-mRNA vaccination sera against different VoIs and VoCs. A Absolute neutralization titers against the respective variant viruses. **B** Fold reduction of neutralization as compared to the wild type WA1 isolate. A list of specific mutations of the clinical isolates can be found in Supplementary Table 1.

Figure 2. Binding activity of post-mRNA vaccination sera against RBD and spike proteins of different VoIs and VoCs. A and C show absolute area under the curve (AUC) binding values against various RBD and spike proteins, B and D show fold-reduction in binding as compare to Wuhan-1 derived wild type proteins.

Supplementary Table 1. Information of viral isolates used in microneutralization assays.

Mutations in NTD and RBD of the Vols and VoCs used in the study				
Isolate ID	Lineage	RBD substitutions	NTD deletions	NTD substitutions
WT	USA-WA1/2020	None	None	None
PV24850	B.1.526	None	None	T95I, D253G
PV25278	B.1.526.2	S477N	None	T95I, D253G
PV26425	B.1.526	E484K	None	T95I, D253G
PV27616	B.1.1.7	E484K, N501Y	H69:V70–, Y144–	E154Q
PV29995	B.1.617.2	L452R, T478K	E156:F157–	G142D, R158G
PV27007	B.1.351	K417N, E484K, N501Y	L241:A243–	D80A, D215G
PV29369	C.37	L452Q, E471Q, F490S	T63:G75–, R246:G252–	D253N

Supplementary Table 2. Sera used in the neutralization assays.

#	sample	Vaccine #	Serostatus*	Sex	Days after 1st dose	Days after 2 nd dose
1	77579	Moderna	neg	Female	30	2
2	76350	Moderna	pos	Male	35	7
3	26973	Moderna	neg	Female	32	5
4	95482	Moderna	neg	Female	31	3
5	93764	Moderna	neg	Female	34	9
6	38258	Moderna	neg	Male	34	5
7	14275	Moderna	pos	Female	30	2
8	22686	Moderna	pos	Female	35	5
9	80902	Moderna	neg	Female	32	6
10	91353	Moderna	pos	Female	32	5
11	66902	Moderna	neg	Female	35	10
12	47380	Moderna	neg	Female	37	9
13	32885	Moderna	neg	Male	31	3
14	30756	Moderna	pos	Female	31	3
15	72329	Moderna	neg	Male	33	6
16	17146	Pfizer	neg	Female	47	22
17	35098	Pfizer	neg	Male	20	6
18	94525	Pfizer	neg	Male	28	7
19	70771	Pfizer	neg	Male	48	27
20	13967	Pfizer	neg	Female	29	8
21	29021	Pfizer	neg	Female	42	23
22	11348	Pfizer	neg	Male	43	22
23	67169	Pfizer	neg	Female	46	22
24	91699	Pfizer	pos	Female	49	29
25	99695	Pfizer	pos	Male	43	21
26	58441	Pfizer	pos	Male	43	25
27	79044	Pfizer	pos	Female	43	22
28	87845	Pfizer	neg	Female	39	20
29	48139	Pfizer	neg	Male	29	9
30	26461	Pfizer	neg	Female	43	21

* Serostatus denotes SARS-CoV-2 antibodies prior to COVID19 vaccination

Vaccine: mRNA SARS-CoV-2 vaccines Moderna (mRNA-1273) or Pfizer (BNT162b2) were administered

441 **Supplementary Figure 1: Phylogenetic tree including all patient isolates used in this study.**

442